Accompanying research of Phase II study of atezolizumab for advanced non-small-cell lung cancer patients not indicative of cytotoxic chemotherapy

Accompanying research of Phase II study of atezolizumab for advanced non-small-cell lung cancer patients not indicative of cytotoxic chemotherapy - 2130-A

Status

Active, not recruiting

Phases

Phase 2

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000033142

Enrollment

Registered

2018-07-07

Start date

2018-06-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients enrolled onto the Phase II safety and efficacy study of atezolizumab in poor performance status patients with previously treated advanced NSCLC (UMIN000032585) 2) Patients providing written informed consent.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
To explore the relationship between immunological state of atezolizumab treated patients having NSCLC with poor performance status	—

Countries

Japan

Contacts

Public ContactYusuke Okuma

Tokyo Metropolitan Komagome Hospital Department of Thoracic Oncology and Respiratory Medicine

y-okuma@cick.jp+81-03-3823-2101

Outcome results